Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation APTCF


Primary Symbol: V.APC.H

Healthcare Biotechnology
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Advanced Proteome Therapeutics Corporation > Huge NR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by unionbrokeron May 29, 2020 10:57am
129 Views
Post# 31087578

RE:RE:Huge NR

RE:RE:Huge NRWhat it’s saying is that there is a company that they can’t name… in an industry where “blockbuster” oncology drugs can offer only months of improved survival, “OVER 15 TIMES” more efficacy seems like a big deal to me…

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities